Vatalanib in Treating Patients With Primary or Secondary Myelodysplastic Syndromes
Study Information
Alliance Study ID: CALGB-10105
NCT Study ID (ClinicalTrials.gov): NCT00072475
Alliance Committee: Leukemia
Disease or Cancer Type: Leukemia & Myelodysplastic Syndromes (MDS)
Alliance Study Chair: Pankaj Gupta, MD
Status: COMPLETED
Study Description
RATIONALE: Vatalanib may be effective in preventing the development of leukemia in patients who have myelodysplastic syndromes.
PURPOSE: This phase II trial is studying vatalanib to see how well it works in treating patients with primary or secondary myelodysplastic syndromes.
Related Publications
For publications related to this and other clinical trials, visit the Alliance Publications Application.
Data Sources & Contacts
Full trial details
For more Information